Argent Biopharma Ltd (MGCLF)

[cbdstockswatcher]

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC’ or ‘the Company’), a European based ‘Seed to Medicine’ bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce successful research results from the ongoing pre-clinical research program that supports and directs novel cannabinoid formulations in the development of treatment for glioblastoma multiforme (‘GBM’), the most aggressive, and so far therapeutically resistant, primary
brain tumour.

The cannabinoid formulations used in this collaborative research program are proprietary and are core to the intellectual property of MGC Pharmaceuticals.

Key Highlights
• This pre-clinical research focuses on the development of cannabinoid formulations specifically tailored for the effective treatment of high-grade brain tumours
• Recent data from NIB, conducted on 14 additional GBM tumour tissue samples, support and direct novel cannabinoid formulations in the treatment of glioblastoma
• Results to date on brain tissue samples from a total of 24 patients (including the 10 patients reported on in July 2019) confirm that the cannabinoid preparations can successfully inhibit tumour cell viability and cause a significant percentage of glioblastoma cells to undergo
“programmed cell death” i.e. apoptosis, after a short time following application

Research also shows CBG termination effects specifically on glioblastoma stem cells, which tend to be extremely resistant to irradiation and chemotherapy treatments


https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-successful-results-from-ongoing-brain-cancer-research-2020-04-22/